Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 15/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23702451 | 0.91 | ATF4 (0.66) | ATF4NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL29689426 | 0.89 | ATF4 (0.60) | ATF4NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL21384520 | 0.89 | ATF4 (0.67) | ATF4LMNA | |
| SCHEMBL21384511 | 0.86 | ATF4 (0.71) | ATF4NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL19134205 | 0.86 | ATF4 (0.73) | ATF4NPC1RAB9AKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL23294544 | 0.85 | ATF4 (0.69) | ATF4NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL16082976 | 0.85 | ATF4 (0.78) | ATF4NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL5123840 | 0.83 | LMNA (0.53) | ATF4RAB9AKMT2AMEN1LMNA | |
| SCHEMBL22362367 | 0.83 | ATF4 (0.71) | ATF4RAB9ALMNA | |
| SCHEMBL22362323 | 0.83 | ATF4 (0.71) | ATF4RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382905-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | EVOTEC INTERNATIONAL GMBH (DE) | 2023-11-30 | — | — | US | disclosed |
| WO-2022084448-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | EVOTEC INTERNATIONAL GMBH (DE) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382905-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | AVPR1B, CRH, CRHR1 | ATF4 10/4885NPC1 1483/4885RAB9A 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.